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Abstract 
Background: Ovarian cancer (OvCa) is a highly aggressive malignoma with a tumor-promoting mi-
croenvironment. Infiltration of polymorphonuclear neutrophils (PMN) is frequently seen, raising the 
question of their impact on tumor development. In that context, effects of PMN on human ovarian 
cancer cells were assessed. 
Methods: Human epithelial ovarian cancer cells were incubated with human PMN, lysate of PMN, or 
neutrophil elastase. Morphological alterations were observed by time-lapse video-microscopy, and the 
underlying molecular mechanism was analyzed by flow cytometry and Western blotting. Functional 
alternations were assessed by an in vitro wound healing assay. In parallel, a large cohort of n=334 
primary OvCa tissue samples of various histological subtypes was histologically evaluated. 
Results: Co-cultivation of cancer cells with either PMN or PMN lysate causes a change of the polygonal 
epithelial phenotype of the cells towards a spindle shaped morphology, causing a cribriform cell growth. 
The PMN-induced alteration could be attributed to elastase, a major protease of PMN. Elastase-induced 
shape change was most likely due to the degradation of membranous E-cadherin, which results in loss of 
cell contacts and polarity. Moreover, in response to elastase, epithelial cytokeratins were downmod-
ulated, in parallel with a nuclear translocation of β-catenin. These PMN-elastase induced alterations of 
cells are compatible with an epithelial-to-mesenchymal transition (EMT) of the cancer cells. Following 
EMT, the cells displayed a more migratory phenotype. In human biopsies, neutrophil infiltration was 
seen in 72% of the cases. PMN infiltrates were detected preferentially in areas with low E-cadherin 
expression. 
Conclusion: PMN in the microenvironment of OvCa can alter tumor cells towards a mesenchymal and 
migratory phenotype. 
Key words: Ovarian cancer, neutrophils, neutrophil elastase, tumor microenvironment, epithelial to mesen-
chymal transition, migration. 
Introduction 
Ovarian cancer (OvCa) is a highly aggressive 
malignoma ranking as the fifth highest cause of can-
cer-related mortality in women in the USA [1]. 
Symptoms of the disease usually develop at a very 
late stage; therefore, about 70% of patients are already 








agnosis (FIGO III or IV). Surgical tumor removal is the 
primary treatment in combination with chemotherapy 
[2, 3]. Despite improved surgical procedures and a 
high primary response to chemotherapy, about 70% of 
patients with advanced ovarian cancer develop a tu-
mor relapse and die from the disease [1]. 
To develop new strategies for further therapeutic 
interventions, a detailed understanding of the molec-
ular mechanisms in ovarian cancer is necessary. In the 
recent years, it became apparent that the microenvi-
ronment greatly affects the development of the tumor 
because it is a major source of tumor promoting fac-
tors in a huge variety of tumors, including OvCa. 
Particularly tumor infiltrating leukocytes can alter 
tumorcells towards an aggressive phenotype [4, 5]. In 
this context, the role of polymorphonuclear neutro-
phils (PMN) in ovarian cancer is of great interest. 
Early data suggested that activated PMN have the 
ability to lyse ovarian cancer cells [6]. However, more 
recent data indicate that a shift of the PMN to T cells 
ratio towards PMN is associated with more aggres-
sive disease in OvCa [7, 8]. Furthermore, it was shown 
that peripheral neutrophils of ovarian cancer patients 
displayed a “proinflammatory phenotype” charac-
terized by an increased production of reactive oxygen 
species and enhanced expression of adhesion mole-
cules, when compared to healthy blood donors. A 
neutrophil–tumor cell contact mediated this pheno-
type changes of PMN [9]. For other (gynecological) 
malignomas, such as breast cancers, an increased 
metastatic potential has been described correlating 
with increased levels of PMN [10, 11]. One hypothesis 
is that PMN-derived matrix-degrading proteases are 
responsible for these changes [12]. To attain metastatic 
ability, carcinoma cells display phenotypic changes, 
particularly an epithelial to mesenchymal transition 
(EMT). EMT is characterized by the loss of the inter-
cellular adhesion molecules E-cadherin, downmodu-
lation of cytokeratins, and a transfer of ß-catenin from 
the cytoplasm to the nucleus [13, 14]. Several studies, 
for example in breast cancer, showed a correlation 
between the loss of E-cadherin and an increased tu-
mor progression, the development of distant metas-
tasis and recurrence of the disease [15, 16]. 
Since the role of PMN in ovarian cancer, espe-
cially with regard to tumor cell migration and ag-
gressiveness, is not yet understood, co-culture ex-
periments of ovarian cancer cells and human PMN 
were performed. PMN, though primarily studied in 
the context of host defense, participate in acute and 
chronic inflammatory disease and most likely also in 
tissue turnover, due to the production of short-lived 
reactive oxygen species, and their diverse and large 
reservoir of proinflammatory cytokines, and tissue 
degrading enzymes, including serine –and metallo-
proteases. We now detected a dyshesion of tumor 
cells when in contact with PMN, and more specifically 
with PMN-derived elastase. Dyshesion was due to the 
enzymatic digestion of the intercellular adhesion 
molecule E-cadherin and resulted in the transition to a 
mesenchymal and migratory phenotype. In a large 
series of human ovarian cancer samples, we could 
detect PMN as a significant portion of tumor infil-
trating immune cells and found an association with 
the expression of the EMT transcription factor ZEB1 
which was also often present in areas where a loss of 
tumor-expressed E-cadherin occurred. Our results 
indicate that PMN are able to alter the ovarian cancer 
towards an aggressive “mesenchymal” phenotype. 
Material and methods 
Tissue samples 
Tissue samples of 334 patients with primary 
ovarian carcinoma who underwent radical surgery 
with the aim of total cytoreduction were investigated. 
Resection specimens were formalin-fixed and paraf-
fin-embedded (FFPE) for diagnostic purposes at the 
Institute of Pathology of the Charité Universi-
tätsmedizin Berlin. 238 patients had been included 
into the TOC project (Tumorbank Ovarian Cancer, 
www.toc-network.de). Scientific use of TOC and 
non-TOC cases has been approved by the ethics 
committee of the Charité. Hematoxylin-eosin-stained 
slides were re-evaluated according to histology by an 
experienced gynecopathologist (SDE). Typing as 
high-grade serous was performed by current WHO 
criteria. Most cases were high-grade serous carcino-
mas (n=213, 63.8%), further histological subtypes 
were low-grade serous carcinomas (n=46, 13.8%), 
(low-grade) endometrioid (n=34, 10.2%), and clear cell 
carcinomas (n=41, 12.3%). The distribution of clini-
co-pathological parameters in the study cohort is 
shown in table 1. 
Immunohistochemistry 
Tissue microarrays with a core size of 1 mm re-
spectively 1.5 mm in diameter (two cores per sample) 
were performed of FFPE resection specimens. Then 
standard hematoxylin/eosin (H&E) staining as well 
as immunohistochemistry was performed. The fol-
lowing primary antibodies were used: anti-CD15 
(DAKO, IS062, 1:50, retrieval condition: pH 6.0), an-
ti-E-cadherin (DAKO, NCH-38, 1:10, retrieval condi-
tion: pH 9.0), ZEB1/AREB6 (abcam, 416A7H10, 1:200, 
retrieval condition: pH 6.0) As secondary antibody 
either the Histofine, Simple Stain universal polymer 
was used (Nichirei, Tokyo, Japan), followed by the 
color reaction using liquid permanent red (Zytomed, 
Berlin, Germany), or the Dako EnVision kit (Dako) 
was used, both followed by counter stain with hema-




toxylin. The amount of E-cadherin expression was 
determined using the Allred score (score 0 – 8), cal-
culated by the sum of staining intensity (0= no; 1= 
weak; 2= moderate; 3= strong) and distribution (0= 
0%; 1= <1%; 2= 1-10%; 3= >10-33%, 4= >33-66%, 5= 
>66-100% positive cells). The number of tumor infil-
trating neutrophils was judged by a semiquantitative 
scoring system (negative: score 0 = 0, moderate: score 
1 =1-19, high: score 2 = > 20 PMN/ 1 mm diameter 
core) and the nuclear translocation of ZEB1 was 
judged present or absent (0 = absent; 1= present). 
 
Table 1. Clinico-pathological parameters: Tissue samples of 
334 patients with primary ovarian carcinoma who underwent 
radical surgery with the aim of total cytoreduction were investi-
gated and the distribution of clinico-pathological parameters in the 






(n=46) n (%) 
endometrioid 
(low-grade) 
(n=34) n (%) 
clear cell 
(n=41) n (%) 
E-Cadherin     
 score 0-1 58 (27.9) 16 (47.1) 8 (23.5) 5 (12.5) 
 score 2-5 110 (52.8) 11 (32.4) 17 (50.0) 15 (37.5) 
 score 6-8 40 (19.2) 9 (26.4) 9 (26.5) 20 (50.0) 
missing 5   1 
ZEB1 nuclear     
 negative 135 (63.4) 15 (44.1) 24 (70.6) 26 (63.4) 
 positive 78 (36.6) 19 (55.9) 10 (29.4) 15 (36.6) 
CD15     
 0/core 53 (24.9) 12 (36.4) 7 (20.6) 15 (38.5) 
 1-19/core 123 (57.7) 14 (42.4) 20 (58.8) 17 (43.6) 
>=20/core 37 (17.4) 7 (21.2) 7 (20.6) 7 (17.9) 
age     
<=60 years 108 (50.7) 18 (52.9) 18 (52.9) 17 (41.5) 
>60 years 105 (49.3) 16 (47.1) 16 (47.1) 24 (58.5) 
FIGO stage     
 FIGO I 16 (7.5) 3 (9.1) 16 (50.0) 24 (58.5) 
 FIGO II 13 (6.1) 2 (6.1) 4 (12.5) 2 (4.9) 
 FIGO III 160 (75.1) 27 (81.8) 12 (37.5) 15 (36.6) 
 FIGO IV 24 (11.3) 1 (3.0) 0 (0) 0 (0.0) 
missing  1 2  
residual tumor     
 none 98 (65.3) 23 (88.5) 8 (100.0) 9 (69.2) 
 any 52 (34.7) 3 (11.5) 0 (0.0) 4 (30.8) 
 n.d. (FIGO I) 16 2 16 24 
 missing 47 6 10 4 
chemotherapy     
 platinum-based  160 (75.5) 26 (76.5) 16 (94.1) 24 (88.0) 
 other  5 (2.4) 0 (0) 0 (0.0) 3 (10.0) 
 none 2 (0.9) 0 1 (5.9) 3 (10.0) 
missing 46 8 17 11 
 
Ovarian cancer cell lines 
SKOV-3 cells were cultivated in McCoys medi-
um (Biochrom AG, Berlin, Germany) containing 10% 
fetal bovine serum and 1% penicillin-streptomycin 
(Invitrogen, Karlsruhe, Germany) at 37°C in a 5% CO2 
humidified atmosphere. OVCAR-3 cells purchased 
from ATCC (Manassas, Virginia, USA) were culti-
vated in RPMI medium (Invitrogen) containing 10% 
fetal bovine serum, 1% penicillin-streptomycin and 
0.01 mg/ml insulin under conditions described above. 
Isolation of PMN and preparation of PMN ly-
sate 
Blood from healthy human donors was extracted 
from peripheral veins and collected in heparin-coated 
syringes (Informed consent was obtained from the 
donors and the procedure was approved by the local 
ethics committee). PMN were isolated by centrifuga-
tion on PolymorphPrep (Axis-Shield PoC AS, Oslo, 
Norway) according to the protocol provided by the 
manufacturer. Isolated PMN were suspended in 
McCoys medium (Biochrom) and used within one 
hour. PMN lysate was prepared by the nitrogen cavi-
tation method. PMN in a concentration of 1x108 were 
suspended in 1ml phosphate buffer and then cavi-
tated in nitrogen for 20 min at 380 psi. 
Co-culture of SKOV-3 with PMN, PMN lysate, 
or PMN elastase  
SKOV-3 (1x105) were plated onLab-TEK cham-
bered slides (Nalge Nunc International, Naperville, 
Illinois, USA) over night for 20 h. The following day, 
isolated PMN (5x105 in 200 µL McCoys medium), 
PMN-lysate (20 µL), or 3 µg PMN-elastase (Calbio-
chem/Merck, Darmstadt, Germany) were added, and 
the morphologic changes of SKOV-3 were recorded 
by time-lapse video microscopy using differential 
interference contrast (DIC). For the time-lapse-video 
experiments, PMN were loaded with Calcein AM (1 
µg/ml; Sigma Aldrich, Taufkirchen, Germany) for 30 
min at 37°C. MDIC and green fluorescence (calcein) 
images were taken every 60 seconds for up to 6 hours 
with a Nikon Ti inverted microscope equipped with 
an Hamamatsu 1394 ORCA-ERA camera, S Fluor 20x 
NA 0.75 objective and a perfect focus system (all Ni-
kon, Tokyo, Japan). Images were analyzed with Image 
J (NIH, Bethesda, MD, USA). 
Protein isolation, SDS-Page, and Western Blot 
Proteins from 5x106 SKOV-3 cells were isolated 
using 150 µL RIPA lysis buffer including protease and 
phosphatase inhibitors (Santa Cruz, Dallas, Texas, 
USA) and the whole lysate was used for Western blot 
analysis of cytokeratin and alpha-smooth muscle actin 
(α-SMA) using a mouse monoclonal antibody to cy-
tokeratin (Santa Cruz, 1 µg/mL), or mouse monoclo-
nal antibody to α-SMA (Santa Cruz, 1 µg/mL). For 
detection of E-cadherin degradation and translocation 
of β-catenin to the nucleus the cell was fractionated 
using the ProteoExtract subcellular proteome extrac-
tion kit (Calbiochem/Merck). With this kit the cyto-
solic fraction, membrane/organelle protein fraction, 
nucleic protein fraction, and cytoskeletal fraction can 
be separated. A rabbit polyclonal antibody to 




E-cadherin was obtained from Santa Cruz and used in 
a final dilution of 1:2000. The antibody to β-Catenin 
was purchased from Becton and Dickinson and used 
in a concentration of 1.25 µg/mL. A non-interfering 
protein assay kit (Calbiochem/Merck) was used for 
determination of protein concentration in the respec-
tive fraction. Lysates or fractions thereof were sepa-
rated by SDS-PAGE (9 % gel), and the proteins were 
transferred to nitrocellulose membranes (Whatman, 
Dassel, Germany). The membranes were then incu-
bated with 5% nonfat milk for 1 h at room tempera-
ture followed by washing with TRIS-buffered sa-
line-Tween-20 (TBST). The membranes were incu-
bated with the respective antibodies at 4°C overnight, 
bound antibody was detected using POX conjugated 
secondary antibodies (all from Jackson Immuno Re-
search, USA) and Amersham ECL Plus Western Blot-
ting Detection system (GE Healthcare, Munich, Ger-
many). As loading controls, β-actin was used, and p84 
for the nuclear fraction (antibodies: Rb pAb to β-actin, 
Abcam, 1:10000; Ms mAb to nuclear matrix protein 
p84, Abcam 0.1 µg/mL).  
Flow cytometry 
SKOV-3 cells were harvested with a cell scraper, 
suspended in FACS buffer (PBS containing 1% bovine 
serum albumin and 0.1% sodium acid) and incubated 
with anti-human E-cadherin (generated in rabbit; 
Santa Cruz), and anti-rabbit-IgG FITC was used as 
secondary antibody. Cells were subjected to flow cy-
tometry (BD LSR II) and analysed with cell quest PRO 
software. 1x104 cells were counted and results are 
expressed as mean fluorescence intensity. 
In vitro wound-healing assay 
SKOV-3 cells (8x105/mL) were plated into 6 well 
plates and grown overnight to near confluence. Cells 
were either treated with neutrophil elastase (2 
µg/mL) or left untreated. Using a pipette tip a cell free 
area was scraped in each well and culture was con-
tinued. Images were taken at 0 h, 4 h and 24 h, and 
cells migrating into the cell free space were quantified.  
Statistical analysis 
Statistical analysis was performed using Graph 
Pad prism software (GraphPad Inc., LaJolla, CA, 
USA) and the appropriate test. Significance levels 
were determined at p<0.05. 
Results 
Neutrophil infiltration and epitheli-
al-to-mesenchymal transition in patients with 
epithelial ovarian carcinoma 
Biopsies of 319 patients with ovarian carcinoma 
were analysed. In 232 (72 %), infiltrating PMN were 
detected as identified by their morphology, expres-
sion of CD15, and of elastase (examples in Fig.1). In 58 
cases, 20 or more PMN were detected per core, and 
2-19 PMN in 174 cases, and 87 cases were considered 
as negative for PMN (0-1 PMN).PMN infiltration (>1 
PMN/tumor) was detected in all histological sub-
types and varied between 61.5% and 79.5% with no 
significant differences between histologic subtypes 
(p=0.157, chi square test). 
The adhesion molecule E-cadherin is strongly 
expressed on epithelial cells, and in 78 cases a strong 
and ubiquitous E-cadherin expression was seen 
(Allred scores 6-8), whereas 153 showed only weak or 
intermediate staining, (Allred scores 2-5), and 85 cases 
revealed no staining. E-cadherin expression did not 
correlate with the numbers of PMN, but correlated 
significantly with histological subtype: median 
E-Cadherin Allred scores were 3 in high-grade serous, 
4 in low-grade serous, 5 in endometrioid, and 6 in 
clear cell carcinomas (p=0.003, Mann-Whitney test).  
As marker for epithelial-to-mesenchymal transi-
tion, expression of ZEB1 in cancer cells was assessed. 
Nuclear expression of ZEB1 was seen in 122 samples 
(37.9%), with positivity rates varying between 29.4% 
and 55.9%. Nuclear expression of ZEB1 did not differ 
between the histologic subtypes (p=0.117, Chi square 
test), and expression of ZEB1 did not correlate with 
the number of infiltrated PMN. There were, however, 
areas within the biopsies that showed a definite clus-
tering of PMN and ZEB1 positive cancer cells (exam-
ple in Fig.1).  
Neutrophils and neutrophil-derived elastase 
cause dyshesion of ovarian cancer cell layers 
The clustering of PMN and ZEB1-positive cells 
prompted a series of experiments on a possible rela-
tionship between PMN and EMT. To this end, effects 
of PMN on ovarian cancer cell lines were assessed. 
Cells grown to confluence in chambered slides were 
co-cultured with isolated PMN having incorporated 
Calcein-AM, and observed by time-lapse video mi-
croscopy. A progressive detachment and dispersion 
of the tumor cells was seen, accompanied by a drastic 
shape change, but no apparent cell death (Data for the 
cell line SKOV-3 are shown in Fig.2; images were ex-
tracted from the video after 0 h, 1 h, 3 h, and 6 h). Es-
sentially similar data were obtained with another cell 
line, OVCAR3 (data not shown). Lysates of PMN also 
caused dyshesion of cancer cells, suggesting a role for 
PMN-derived proteases. A likely candidate is elastase, 
and indeed purified elastase induced dyshesion of 
tumor cells, accompanied by a shape change from a 
round to ovoid phenotype to an elongated and spin-
dle-shaped appearance, similar to the effects seen 
with PMN-lysates.  





Figure 1. Examples of tissue specimens derived from patients with epithelial ovarian cancer: On the left panel, tissue with dense expression of PMN, on 
the right panel with low expression of PMN are shown (A, B), and corresponding staining for E-cadherin (C, D), and ZEB1 (E, F). The inserts show a digital zoom 
of selected areas, and the arrows show typical examples. In (G) a dense infiltration of elastase positive PMN is shown. 
 
Degradation of E-cadherin by PMN lysate/ 
neutrophil elastase 
A potential target for neutrophil elastase on tu-
mor cells is the adhesion molecule E-cadherin, which 
mediates the mutual binding. By indirect immuno-
fluorescence and by flow cytometry, E-cadherin could 
be detected on SKOV-3 cells. Incubation of cells with 
either neutrophil elastase (3 µg/mL) or PMN lysate 
(50 µL/mL) for 5 h to 24 h, caused a degradation of 
E-cadherin as seen by using an antibody that binds to 
the N-terminus of E-cadherin (Fig. 3). Flow cytometry 
showed a decrease of surface E-cadherin expression 
when cells were treated with elastase (on average 
(n=3) reduction of mean fluorescence intensity of 
70%). PMN lysates also reduced E-cadherin expres-
sion (on average by 30%) (Fig. 3A). Degradation of 
E-cadherin by PMN lysate or elastase was confirmed 
by Western blot analysis. Membrane expression was 
reduced, whereas cytosolic E-cadherin was not af-
fected, being compatible with the notion that elastase 
targeted only the surface-expressed E-cadherin (one 
of three experiments is shown in Fig. 3B). 
Induction of an epithelial-to-mesenchymal 
transition (EMT) of SKOV-3 by elastase 
Whether dyshesion and shape changes of 
SKOV-3 are associated with an induction of EMT was 
evaluated in the next set of experiments. To this end, 
expression of cytokeratins as a marker for epithelial 
cells was assessed. By Western blotting, a decrease of 
cytokeratins was seen in cells treated with either 




PMN, PMN lysate, or elastase. Concomitantly, 
β-catenin expression increased in the nuclear fraction, 
indicating a translocation of β-catenin to the nucleus 
as it occurs in the course of EMT (Fig. 4).  
 
Figure 2. Effect of PMN on SKOV-3 monolayers: Tumor cells were grown to near confluence and PMN, PMN elastase, or PMN lysate were added and the 
interaction was observed by time-lapse video microscopy. Images were selected from the video clip after 0 h, 1 h, 3 h, and 6 h, respectively. The data are repre-






Figure 3. Effect of elastase or PMN lysate on E-cadherin surface 
expression: A By flow cytometry E-cadherin expression on SKOV-3 was 
determined on untreated cells (thin line) and after addition of elastase (left 
panel; thick lines) or PMN-lysate (right panel; thick line). Shown are repre-
sentative examples. B Western blot analysis revealed a significant reduction of 
E-cadherin in the cell membrane but not in the cytoplasm (β-actin was used as 
loading control, relative densities were calculated with Quantity One Software 
(BioRad). Data shown are representative of three experiments. 
 
Functional consequences of EMT in SKOV-3  
To assess functions of SKOV-3 following EMT, 
mobility of cells was tested using an in vitro wound 
healing assay. As seen in the example in Fig. 4, fol-
lowing treatment with elastase, approximately 2.1 
fold more cells migrated into the depleted area com-
pared to untreated cells. On average, 26.7% of the 
depleted area was overgrown again compared to 
12.7% in the control (mean of three experiments).  





Figure 4. Induction of EMT in SKOV-3 by elastase or PMN lysate: A 
Cytokeratin (upper panel) was determined in the cell lysates of untreated 
SKOV-3 or of SKOV-3 being exposed to either PMN elastase or PMN lysate. 
The antibody recognized three cytokeratins, expression of which declined in 
treated cells. With β-actin as loading control, it was seen that the density of the 
cytokeratin bands declined in treated cells (the numbers indicate the relative 
density obtained for the 55 kD band. Data of one of three experiments is 
shown). B In SKOV-3 treated with PMN lysate, a translocation into the nucleus 
of β-catenin was seen. As loading control the nuclear antigen p84 was used (one 





Figure 5. Migration of SKOV-3 cells: A Cells were grown to confluence. 
Then a defined area was scratched (time 0 h) and the repopulation after 24h was 
determined by untreated cells or cells that had been pretreated with elastase. B 






The role of neutrophils in tumors is controver-
sially discussed: on the one hand, induction of tumor 
cell apoptosis [17] or killing [18, 19] has been de-
scribed, on the other hand an association with tumor 
progression, presumably due to promotion of metas-
tasis [20], of angiogenesis or by dampening the an-
ti-cancer immune reaction [21]. Moreover, neutro-
phil-derived elastase promotes tumor progression by 
increasing cell growth and survival [22]. Especially for 
ovarian cancers, it has been shown that (indirect) de-
pletion of neutrophils in murine models causes dis-
ease stabilization, thus a pivotal role in ovarian cancer 
is likely [4]. 
In our collection with ovarian cancer samples, 
neutrophil infiltration into tumors was seen in the 
majority of cases. The infiltrated cells were not ho-
mogenously distributed; areas with dense PMN infil-
trates were seen, but also those lacking infiltrating 
cells. Overall, the number of infiltrating neutrophils 
did not correlate with severity of disease or histologic 
classification. However, due to the inhomogeneous 
pattern, quantification has to be interpreted with 
some caution.  
Epithelial cells and in that respect also ovarian 
tumor cells adhere to each other via E-cadherin. In our 
very large patient cohort E-cadherin expression was 
lowest in the most aggressive, high-grade serous 
subgroup as compared to the histological subtypes of 
the low-grade group. These results corroborate with 
findings that a loss of E-cadherin is associated with 
poor outcome in ovarian cancer patients [23]. In addi-
tion, a decreased E-cadherin expression was associ-




ated with increased peritoneal metastasis and fre-
quently seen in high-grade serous cancers [24]. Loss of 
surface-associated E-cadherin is – at least in part – due 
to cleavage by neutrophil-derived elastase, a fact that 
we confirmed in our vitro study. One have to keep in 
mind that a plethora of factors abundant in infiltrated 
cells of the tumor microenvironment , and in particu-
lar PMN, such as TGF-β [25], amphiregulin [26], 
HIF-1α [27], or FGF-2 [28] are also able to induce 
E-cadherin downregulation in ovarian cancer. Loss of 
E-cadherin and the subsequent weakening of the 
cell-to-cell contacts by loss of cell polarity is consid-
ered to be a crucial step in the epitheli-
al–to-mesenchymal transition process [29].  
Elastase is one of the major effector proteins in 
neutrophils [30] linking the loss of E-cadherin to the 
infiltrating neutrophils. That E-cadherin is rapidly 
recycled from intracellular stores or de novo synthe-
sized might explain the fact that there is no numerical 
correlation between E-cadherin expression and the 
leukocyte number. Of note, although elastase is the 
most likely effector in E-cadherin cleavage, other 
PMN-derived proteases cannot be ruled out.  
Cleavage of surface-associated E-cadherin has 
numerous consequences; among those loss of cellular 
polarity and shape change; enhanced motility of the 
cells, and induction of epithelial-to-mesenchymal 
transition (EMT). Expression of ZEB1 in biopsies of 
patients is indicative of the latter, and although the 
overall number of ZEB1 positive cells did not correlate 
with the number of infiltrating cells, ZEB1 positive 
cells were accumulated in areas of dense neutrophil 
infiltrates.  
A definite link between PMN and induction of 
EMT was established by our in vitro experiments. 
PMN and, more specifically, PMN-derived elastase 
cause a dyshesion of ovarian cancer cells grown in 
monolayers. Elastase cleaved surface E-cadherin of 
ovarian cancer cells and induced EMT, as determined 
by loss of cytokeratins and translocation into the nu-
cleus of β-catenin. Moreover, an increased migratory 
potential of the ovarian cancer cells was observed. 
These findings are in line with data reported for pan-
creas epithelial cells in pancreatitis or pancreatic can-
cer cells [31], for lung cancer [32], colorectal cancer 
[33], or hepatocellular carcinoma [34]. The transition 
from an epithelial towards a mesenchymal phenotype 
is usually associated with a more aggressive pheno-
type of different tumors [35].  
Conclusion 
Human biopsies of a large tumor cohort showed 
neutrophil infiltrates as common feature in ovarian 
cancer. In the majority of cases, loss of E-cadherin on 
tumor cells was detected and EMT was seen. In vitro 
data established a link between neutrophil-derived 
elastase, loss of E-cadherin, and EMT, providing an 
explanation why ovarian cancer patients with an in-
creased level on neutrophils have a poorer prognosis. 
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